IntegraGen (ALINT) Stock Overview
Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ALINT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
IntegraGen SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.18 |
| 52 Week High | €0.73 |
| 52 Week Low | €0.12 |
| Beta | 0.48 |
| 1 Month Change | 14.65% |
| 3 Month Change | 14.29% |
| 1 Year Change | -65.05% |
| 3 Year Change | -86.05% |
| 5 Year Change | -91.22% |
| Change since IPO | -98.02% |
Recent News & Updates
Recent updates
IntegraGen SA (EPA:ALINT) Looks Inexpensive After Falling 41% But Perhaps Not Attractive Enough
Oct 03
Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S
Dec 14Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S
Aug 28There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues
Feb 17Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now
Apr 19Shareholder Returns
| ALINT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 18.8% | -1.1% | 1.4% |
| 1Y | -65.0% | 317.8% | 1.9% |
Return vs Industry: ALINT underperformed the French Biotechs industry which returned 327.6% over the past year.
Return vs Market: ALINT underperformed the French Market which returned 2.8% over the past year.
Price Volatility
| ALINT volatility | |
|---|---|
| ALINT Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALINT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALINT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 40 | Berengere Genin | integragen.com |
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts.
IntegraGen SA Fundamentals Summary
| ALINT fundamental statistics | |
|---|---|
| Market cap | €1.19m |
| Earnings (TTM) | -€1.55m |
| Revenue (TTM) | €6.61m |
Is ALINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINT income statement (TTM) | |
|---|---|
| Revenue | €6.61m |
| Cost of Revenue | €5.84m |
| Gross Profit | €768.00k |
| Other Expenses | €2.32m |
| Earnings | -€1.55m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 11.62% |
| Net Profit Margin | -23.43% |
| Debt/Equity Ratio | 119.8% |
How did ALINT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/25 13:22 |
| End of Day Share Price | 2026/02/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IntegraGen SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arnaud Guérin | Portzamparc BNP Paribas |